EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

QTc Interval Prolongation in Drug-Resistant Tuberculosis Treated with Bedaquiline and Delamanid Under Programmatic Conditions

Oki Nugraha Putra

Pharmacology and Clinical Pharmacy Research · 02.08.2025 · 10 (2)

DOI: 10.15416/pcpr.v10i2.60987 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology and Clinical Pharmacy Research, online erschienen am 02.08.2025. Verfasst von Oki Nugraha Putra. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The cardiac safety of regimens containing bedaquiline and delamanid is not well-established, especially in Indonesia. This study aimed to analyze QTc interval during six months of treatment and factors associated with QTc interval prolongation.

Methods

A prospective cohort of drug-resistant tuberculosis (DR-TB) patients received regimens containing bedaquiline and delamanid between September 2022 and May 2023 at the outpatient department of MDR-TB of the Dr. Soetomo Hospital. Patients were divided into bedaquiline and bedaquiline-delamanid-containing regimens groups, respectively. QTc interval was evaluated before and until the sixth month of treatment using ECG. QTc interval prolongation was categorized as clinically significant if ≥ 500 ms or QTc difference ≥ 60 ms.

Results

Sixty-three (63) DR-TB patients enrolled in this cohort consisting of 51 and 12 patients in the bedaquiline and the bedaquilin-delamanid group, respectively. Grade II and III of QTc interval prolongation was higher in the bedaquiline-delamanid than in the bedaquiline group, 41.7% vs. 8.3%; 15.7% vs. 1.9%, respectively, P-value 0.084. However, the mean difference in QTc interval was < 60 ms between the two groups during six months of treatment, with a P-value ≥ 0.05. Maximum QTc interval was observed after four months of treatment. No patients had serious cardiac events during the study period. Potassium and calcium levels were associated with QTc interval prolongation.

Conclusion

Regimens containing bedaquiline-delamanid provide a good safety profile without serious signs of QTc interval prolongation in patients with DR-TB. These regimens should be considered as a programmatic treatment in a clinical setting.Keywords: Bedaquiline; Delamanid; DR-TB; QTc Interval

Zitieren

APA

Putra, O. N. (2025). QTc Interval Prolongation in Drug-Resistant Tuberculosis Treated with Bedaquiline and Delamanid Under Programmatic Conditions. Pharmacology and Clinical Pharmacy Research, 10(2). https://doi.org/10.15416/pcpr.v10i2.60987

Vancouver

Putra ON. QTc Interval Prolongation in Drug-Resistant Tuberculosis Treated with Bedaquiline and Delamanid Under Programmatic Conditions. Pharmacology and Clinical Pharmacy Research. 2025;10(2). doi:10.15416/pcpr.v10i2.60987

BibTeX
@article{Putra2025,
  author = {Putra, Oki Nugraha},
  title = {QTc Interval Prolongation in Drug-Resistant Tuberculosis Treated with Bedaquiline and Delamanid Under Programmatic Conditions},
  journal = {Pharmacology and Clinical Pharmacy Research},
  year = {2025},
  volume = {10},
  number = {2},
  doi = {10.15416/pcpr.v10i2.60987}
}
Kostenlos starten →